Jelena Arnautovic
Cardiovascular Disease · Sterling Heights, MINPI 1578982476
Payments from drug & device makers
Across 264 payments — averaging $63.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$9K
- Abbott$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$624
- Kestra Medical Technology Services, Inc.$610
- Shockwave Medical, Inc$609
- Boehringer Ingelheim$506
- plus $4K from 33 others
What the payments were for
- Speaking & faculty fees$7,87547%
- Travel & lodging$6724%
- Food & beverage$7,74946%
- Education$5503%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 27 | $9,097 |
| Abbott | 12 | $1,067 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 19 | $624 |
| Kestra Medical Technology Services, Inc. | 9 | $610 |
| Shockwave Medical, Inc | 4 | $609 |
| Boehringer Ingelheim | 21 | $506 |
| Novartis | 26 | $466 |
| Boston Scientific | 6 | $388 |
| Amgen | 17 | $370 |
| Inari Medical, Inc. | 7 | $354 |
| AstraZeneca | 18 | $349 |
| Johnson & Johnson | 17 | $326 |
| Biotronik Inc. | 2 | $234 |
| Abiomed | 9 | $216 |
| Novo Nordisk | 4 | $209 |
| Alnylam Pharmaceuticals Inc. | 12 | $198 |
| E.r. Squibb & Sons, L.L.C. | 11 | $172 |
| Actelion Pharmaceuticals US, Inc. | 3 | $151 |
| Merck | 7 | $105 |
| Livanova USA, Inc. | 2 | $103 |
| Bard Peripheral Vascular, Inc. | 1 | $86 |
| Scpharmaceuticals Inc. | 3 | $63 |
| Chiesi USA, Inc. | 3 | $59 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $54 |
| Edwards Lifesciences | 2 | $45 |
| Lexicon Pharmaceuticals, Inc. | 2 | $42 |
| Bridgebio Pharma, Inc. | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 2 | $39 |
| Heartflow, Inc. | 2 | $37 |
| Philips North America LLC | 2 | $37 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $36 |
| Convatec Inc. | 1 | $27 |
| Cleerly, Inc. | 1 | $26 |
| CMP Pharma, Inc. | 1 | $23 |
| Recor Medical Inc | 1 | $18 |
| Baxter Healthcare | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $15 |
| Teleflex LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$8,621
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$609
- Assure WCD$496
- CardioMEMS HF System$283
- JARDIANCE$227
- LifeVest$215
- Ensite Cardiac Mapping System$208
- HeartMate 3 Left Ventricular Assist Device$205
- FLOWTRIEVER CATHETER, S$175
- CT THROMBECTOMY SYSTEM KIT$175
- HeartMate 3 Left Ventricular Dev$164
- WATCHMAN FLX$149
- Rivacor 7 DR-T$139
- Acticor 7 VR-T DX$139
- BioMonitor$139
- Edora 8 DR-T$139
- EKOSONIC$138
- Repatha$126
- Wegovy$125
- XARELTO$107
How this compares
$16,846 in reported general payments places this provider in the 75th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 105 | $131,594 |
| JardianceEmpagliflozin | 100 | $111,497 |
| EntrestoSacubitril/Valsartan | 65 | $80,407 |
| XareltoRivaroxaban | 44 | $54,664 |
| FarxigaDapagliflozin Propanediol | 42 | $45,148 |
| Repatha SureclickEvolocumab | 20 | $19,330 |
| BrilintaTicagrelor | 13 | $5,721 |
| Metoprolol Succinate | 306 | $5,111 |
| Atorvastatin Calcium | 248 | $3,083 |
| Ranolazine ErRanolazine | 37 | $2,017 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $1,980 |
| Losartan Potassium | 180 | $1,916 |
| Ezetimibe | 44 | $1,532 |
| Nifedipine ErNifedipine | 37 | $1,377 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 66 | $1,112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $9,097 | $131,594105 claims |
| Boehringer IngelheimJardiance | $506 | $111,497100 claims |
| NovartisEntresto | $466 | $80,40765 claims |
| Johnson & JohnsonXarelto | $326 | $54,66444 claims |
| AstraZenecaFarxiga, Brilinta | $349 | $50,86855 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Sterling Heights
- Stanley ChetcutiAnn Arbor$4.3M
- Sandeep KhuranaGrandville$2.3M
- Victor MolesAnn Arbor$2.1M
- Jihad MustaphaGrand Rapids$1.9M
- Marschall RungeAnn Arbor$1.8M
- Sara SaberiAnn Arbor$1.6M
- Brian OneillDetroit$1.4M
- Vallerie McLaughlinAnn Arbor$1.4M
- Ahmad MizyedYpsilanti$1M
- Waleed DoghmiMidland$968K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.